☰

Liv H. Johannessen, Ph.D. - Publications

Affiliations: 
2007-2012 Cancer Inflammation Program National Cancer Institute at Frederick, MD 21702 USA, Frederick, MD, United States 
 2012- BCMP Harvard University, Cambridge, MA, United States 
Area:
CDKs, Transcription, Immunology
Tree Info Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Arnett A, Moo KG, Flynn KJ, Sundberg TB, Johannessen L, Shamji AF, Gray NS, Decker T, Zheng Y, Gersuk VH, Rahman ZS, Levy DE, Marié IJ, Linsley PS, Xavier RJ, et al. The CDK8 inhibitor DCA promotes a tolerogenic chemical immunophenotype in CD4 T cells via a novel CDK8-GATA3-FOXP3 pathway. Molecular and Cellular Biology. MCB0008521. PMID 34124936 DOI: 10.1128/MCB.00085-21  0.468
2020 Johannessen L, Ke N, Sawant P, Dworakowski W, D'Ippolito A, Hu S, Rajagopal N, Eaton M, Hodgson G. Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer. Journal of Clinical Oncology. 38: 3585-3585. DOI: 10.1200/Jco.2020.38.15_Suppl.3585  0.335
2019 Hu S, Marineau JJ, Rajagopal N, Hamman KB, Choi YJ, Schmidt DR, Ke N, Johannessen L, Bradley MJ, Orlando DA, Alnemy SR, Ren Y, Ciblat S, Winter DK, Kabro A, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Research. PMID 31064851 DOI: 10.1158/0008-5472.Can-19-0119  0.311
2019 Ke N, Johannessen L, Rajagopal N, Orlando D, Carulli J, Hodgson G. Abstract 4409: Prospective identification of RB pathway alterations predict response to SY-1365, a selective CDK7 inhibitor, in a panel of high-grade serous ovarian cancer (HGSOC) patient derived xenograft (PDX) models Cancer Research. 79: 4409-4409. DOI: 10.1158/1538-7445.Sabcs18-4409  0.327
2019 Johannessen LH, Hu S, Ke N, D'Ippolito A, Rajagopal N, Marineau J, Savinainen A, Zamboni W, Hodgson G. Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C091  0.356
2018 Hatcher JM, Wang ES, Johannessen L, Kwiatkowski N, Sim T, Gray NS. Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8. Acs Medicinal Chemistry Letters. 9: 540-545. PMID 29937979 DOI: 10.1021/Acsmedchemlett.8B00011  0.554
2018 Konstantinopoulos PA, Hodgson G, Rajagopal N, Johannessen L, Liu JF, Kirschmeier PT, Zhou S, Tran CA, Orlando D, Fritz C, Tomaso Ed, Matulonis UA. Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo Cancer Research. 78: 1525-1525. DOI: 10.1158/1538-7445.Am2018-1525  0.389
2017 Johannessen L, Sundberg TB, O'Connell DJ, Kolde R, Berstler J, Billings KJ, Khor B, Seashore-Ludlow B, Fassl A, Russell CN, Latorre IJ, Jiang B, Graham DB, Perez JR, Sicinski P, et al. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nature Chemical Biology. PMID 28805801 DOI: 10.1038/Nchembio.2458  0.546
2016 Sundberg TB, Liang Y, Wu H, Choi HG, Kim ND, Sim T, Johannessen L, Petrone A, Khor B, Graham DB, Latorre IJ, Phillips AJ, Schreiber SL, Perez J, Shamji AF, et al. Development of Chemical Probes for Investigation of Salt-Inducible Kinase Function In Vivo. Acs Chemical Biology. PMID 27224444 DOI: 10.1021/Acschembio.6B00217  0.556
2015 Tan L, Akahane K, McNally R, Reyskens KM, Ficarro SB, Liu S, Herter-Sprie GS, Koyama S, Pattison MJ, Labella KM, Johannessen L, Akbay EA, Wong KK, Frank DA, Marto JA, et al. Development of Selective Covalent JAK3 Inhibitors. Journal of Medicinal Chemistry. PMID 26258521 DOI: 10.1021/Acs.Jmedchem.5B00710  0.573
2012 Johannessen L, Remsberg JR, Ivanova A, Gaponenko V, Khavrutskii L, Tarasov SG, Dean M, Kates J, Tarasova NI. Abstract LB-426: Potent inhibitors of RAS pathways that bind directly to Ras proteins Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-426  0.334
2011 Johannessen L, Remsberg J, Gaponenko V, Adams KM, Barchi JJ, Tarasov SG, Jiang S, Tarasova NI. Peptide structure stabilization by membrane anchoring and its general applicability to the development of potent cell-permeable inhibitors. Chembiochem : a European Journal of Chemical Biology. 12: 914-21. PMID 21365731 DOI: 10.1002/Cbic.201000563  0.378
Show low-probability matches.